 Home > Medical News > Latest Medical News > Notice on the public solicitation of opinions on the Technical Guidelines for the Clinical Development of Anti-tumor Antibody Conjugated Drugs

Notice on the public solicitation of opinions on the Technical Guidelines for the Clinical Development of Anti-tumor Antibody Conjugated Drugs

 Last Update: 2022-10-02
 Source: Internet
 Author: User

Tags

antifreeze chemical name

anesthesia drugs chart

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Notice on the public solicitation of opinions on the Technical Guidelines for the Clinical Development of Anti-tumor Antibody Conjugated Drugs

Release date: 20220915

The development of biopharmaceutical technology has promoted the rapid development of antibody-conjugated drugs, especially in the field of tumor treatment, and the research and development of antibody-conjugated anti-tumor drugs has continued to grow

In order to make suggestions on the issues requiring special attention in the clinical research and development of antibody-coupled anti-tumor drugs, and to guide enterprises to carry out more scientific clinical research and development, the Drug Evaluation Center organized and wrote the "Technical Guidelines for the Clinical Development of Anti-tumor Antibody Conjugated Drugs", forming a draft for comments for the reference

We sincerely welcome all sectors of the community to put forward valuable comments and suggestions on the draft for comments, and timely feedback to us for follow-up improvement

Please send your feedback to the email address of the following contact:

Contact: Charlene, Song Yuanyuan

Contact: xialin@cde.

Thank you for your participation and great support

Drug Evaluation Center of the State Drug Administration

September 15, 2022

We sincerely welcome all sectors of the community to put forward valuable comments and suggestions on the draft for comments, and timely feedback to us for follow-up improvement

Please send your feedback to the email address of the following contact:

Contact: Charlene, Song Yuanyuan

Contact: xialin@cde.

Thank you for your participation and great support

Drug Evaluation Center of the State Drug Administration

September 15, 2022

Related Attachments

serial number

The attachment name

Technical Guidelines for the Clinical Development of Anti-tumor Antibody Conjugated Drugs (Draft for Solicitation of Comments).

serial number	The attachment name
1	Technical Guidelines for the Clinical Development of Anti-tumor Antibody Conjugated Drugs (Draft for Solicitation of Comments). pdf
2	The feedback form of the "Technical Guidelines for the Clinical Development of Anti-tumor Antibody Conjugated Drugs (Draft for Comments)" . docx
3	The drafting instructions for the technical guidelines for the clinical development of anti-tumor antibody conjugated drugs (draft for comments) . pdf

Serial Number Attachment Name Serial Number Attachment Name Serial Number Attachment Name 1 Technical Guidelines for the Clinical Development of Antitumor Antibody Conjugated Drugs (Draft for Comments).
pdf 2 Technical Guidelines for the Clinical Development of Anti-Tumor Antibody Conjugated Drugs (Draft for Comment) Feedback Form .
docx 3 Technical Guidelines for the Clinical R&D of Anti-Tumor Antibody Conjugated Drugs (Draft for Solicitation of Comments).
pdf 1 Technical Guidelines for the Clinical R&D of Anti-tumor Antibody Conjugated Drugs (Draft for Solicitation of Comments).
pdf 11 Technical Guidelines for the Clinical Development of Anti-tumor Antibody Conjugated Drugs (Draft for Comment).
pdf Technical Guidelines for the Clinical Development of Anti-tumor Antibody Conjugated Drugs (Draft for Comment).
pdf Technical Guidelines for the Clinical Development of Anti-tumor Antibody Conjugated Drugs (Draft for Comment).
pdf 2 Feedback Form for the Clinical R&D of Anti-Tumor Antibody Conjugated Drugs (Draft for Solicitation of Comments) .
docx 22 Feedback Form for the Clinical R&D of Anti-Tumor Antibody Conjugated Drugs (Draft for Comment)Feedback Form .
docx Feedback Form for the Clinical R&D of Anti-Tumor Antibody Conjugated Drugs (Draft for Solicitation of Comments).
docx Feedback Form for the Clinical R&D of Anti-Tumor Antibody Conjugated Drugs (Draft for Solicitation of Comments).
docx 3 Technical Guidelines for the Clinical Development of Anti-tumor Antibody Conjugated Drugs (Draft for Solicitation of Comments).
pdf 33 Technical Guidelines for the Clinical Development of Anti-Tumor Antibody Conjugated Drugs (Draft for Solicitation of Comments)Drafting Instructions.
pdf Drafting Instructions for the Clinical Development of Anti-Tumor Antibody Conjugated Drugs (Draft for Solicitation of Comments).
pdf Drafting Instructions for the Clinical Development of Anti-Tumor Antibody Conjugated Drugs (Draft for Solicitation of Comments).
pdf

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.